Menu Search
Equities

Genetic Technologies Ltd

GTG:ASX

Genetic Technologies Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.12
  • Today's Change-0.005 / -4.00%
  • Shares traded6.44k
  • 1 Year change-60.00%
  • Beta0.9081
Data delayed at least 20 minutes, as of May 17 2024 05:19 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Genetic Technologies Limited is an Australia-based diversified molecular diagnostics company. The Company is engaged in providing genomics-based tests on health, wellness and serious disease through its geneType and EasyDNA brands. The Company offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The Company has a proprietary risk stratification platform that integrates clinical and genetic risk to deliver outcomes to physicians and individuals. The Company operates through three segments: EasyDNA, AffinityDNA, and GeneType / Corporate. EasyDNA segment relates to EasyDNA branded test sales and expenses. AffinityDNA segment relates to AffinityDNA branded test sales and expenses. GeneType / Corporate segment relates to geneType branded test sales and expenses, including corporate charges. The GeneType test is for breast cancer, colorectal cancer, ovarian cancer, prostate cancer, coronary artery disease and mor

  • Revenue in AUD (TTM)8.49m
  • Net income in AUD-12.71m
  • Incorporated1987
  • Employees60.00
  • Location
    Genetic Technologies Ltd60-66 Hanover St, FitzroyMELBOURNE 3065AustraliaAUS
  • Phone+61 39415-1135
  • Fax+61 38412-7040
  • Websitehttps://www.gtglabs.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.